Leverkusen, Germany-based Bayer has promoted Robert LaCaze to executive vice president of its new oncology strategic business unit, part of the firm's pharmaceutical division.
LaCaze joins the pharmaceutical division's executive committee, and will be responsible for implementing the new unit's accelerated development model for new oncology therapies.
He first joined Bayer in 2015 and most recently served as senior vice president and head of global oncology therapeutic area at the firm.
Prior to this, LaCaze spent 27 years at Bristol-Myers Squibb, holding a series of increasingly senior oncology-focused managerial roles, before becoming senior vice president and head of product and portfolio strategy at Bristol-Myers Squibb in 2014.
Dieter Weinand, head of the Bayer Pharmaceutical executive committee, said: “We are delighted to have an executive with Robert LaCaze's experience and talent lead the Oncology Strategic Business Unit.
“I am confident that he will contribute his expertise and foresight to help strengthen our efforts in the fight against cancer.”